Study design (if review, criteria of inclusion for studies)
Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
Participants
Pulmonary Cystic Fibrosis - 14 Years and older (Child, Adult, Older Adult)
Interventions
Device: SIMEOX
Outcome measures
Respiratory score of CFQ-R questionnaire|Variation of forced expiratory volume in 1 second (FEV1)|Total score of CFQ-R questionnaire|Safety of use assessed by incidence of Treatment-Emergent Adverse Events|Satisfaction assessed by "Treatment Satisfaction Questionnaire for Medication"(TSQM) questionnaire|Acceptability assessed by the number of uses of SIMEOX® device|Pulmonary forced vital capacity (FVC)|FEV1/ FVC ratio|Forced expiratory flow|Total lung capacity (TLC)|Residual functional capacity (RFC)|Static lung compliance|Inspiratory capacity|Airway resistance|Diffusion capacity for carbon monoxide|Quality of life assessed by EQ-5D 5L questionnaire : a standardized instrument for measuring generic health status|Physical activity assessed by step counts and moderate-to-vigorous physical activity|Sleep quality assessed by sleep efficiency and fragmentation|Fatigue assessed by VAS (visual analogue scale)|Dyspnea assessed by mMRC (Modified Medical Research Council) score|Exacerbation rate|First exacerbation|Hospitalization rate|Hospitalization duration|Antibiotic therapy